A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol
Michael S Hofman, Declan G Murphy, Scott G Williams, Tatenda Nzenza, Alan Herschtal, Richard De Abreu Lourenco, Dale L Bailey, Ray Budd, Rodney J Hicks, Roslyn J Francis, Nathan Lawrentschuk
BJU INTERNATIONAL | WILEY | Published : 2018
BACKGROUND: Accurate staging of patients with prostate cancer (PCa) is important for therapeutic decision-making. Relapse after surgery or radiotherapy of curative intent is not uncommon and, in part, represents a failure of staging with current diagnostic imaging techniques to detect disease spread. Prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) is a new whole-body scanning technique that enables visualization of PCa with high contrast. The hypotheses of this study are that: (i) PSMA-PET/CT has improved diagnostic performance compared with conventional imaging; (ii) PSMA-PET/CT should be used as a first-line diagnostic test for staging;..View full abstract
We would like to thank all the staff at the Centre for Biostatistics and Clinical Trials (BaCT) and Cancer Imaging at the Peter MacCallum Cancer Centre, Melbourne for trial coordination including Aneta Matera (clinical trial manager), Petra Marusic (clinical research coordinator), Dr Jason Callahan (core lab project manager) and Dr Amir Iravani (core lab physician). This clinical trial is funded by a grant from the Movember Foundation through Prostate Cancer Foundation of Australia's Research Program, and administered through the University of Melbourne. Michael Hofman is additionally supported by a Clinical Fellowship Award from the Peter MacCallum Foundation.